IS4880A - Innlyksa kompexar af arýl - heterósýklískum söltum - Google Patents

Innlyksa kompexar af arýl - heterósýklískum söltum

Info

Publication number
IS4880A
IS4880A IS4880A IS4880A IS4880A IS 4880 A IS4880 A IS 4880A IS 4880 A IS4880 A IS 4880A IS 4880 A IS4880 A IS 4880A IS 4880 A IS4880 A IS 4880A
Authority
IS
Iceland
Prior art keywords
aryl
heterocyclic salts
internal complexes
complexes
internal
Prior art date
Application number
IS4880A
Other languages
English (en)
Other versions
IS2524B (is
Inventor
Charles Johnson Kevin
Kim Yesook
Mysore Shanker Ravi
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4880A publication Critical patent/IS4880A/is
Publication of IS2524B publication Critical patent/IS2524B/is

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Soil Conditioners And Soil-Stabilizing Materials (AREA)
  • Seasonings (AREA)
  • Machine Translation (AREA)
IS4880A 1996-05-07 1998-10-27 Innlyksuflókar arýl-heterósýklískra salta. IS2524B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1920496P 1996-05-07 1996-05-07
PCT/IB1997/000321 WO1997041896A2 (en) 1996-05-07 1997-04-01 Inclusion complexes of aryl-heterocyclic salts

Publications (2)

Publication Number Publication Date
IS4880A true IS4880A (is) 1998-10-27
IS2524B IS2524B (is) 2009-07-15

Family

ID=21791976

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4880A IS2524B (is) 1996-05-07 1998-10-27 Innlyksuflókar arýl-heterósýklískra salta.

Country Status (47)

Country Link
US (2) US6232304B1 (is)
EP (1) EP0900088B1 (is)
JP (1) JP3579060B2 (is)
KR (1) KR20000010823A (is)
CN (1) CN1216923A (is)
AP (1) AP796A (is)
AR (2) AR007002A1 (is)
AT (1) ATE257714T1 (is)
AU (1) AU713711B2 (is)
BG (3) BG64474B1 (is)
BR (1) BR9709213A (is)
CA (1) CA2251912C (is)
CO (1) CO4600677A1 (is)
CZ (1) CZ297847B6 (is)
DE (1) DE69727218T2 (is)
DK (1) DK0900088T3 (is)
DZ (1) DZ2220A1 (is)
EA (1) EA001731B1 (is)
EG (1) EG24135A (is)
ES (1) ES2212809T3 (is)
GE (1) GEP20074185B (is)
GT (1) GT199700044A (is)
HN (1) HN1997000039A (is)
HR (1) HRP970237B1 (is)
HU (1) HU222451B1 (is)
ID (1) ID16866A (is)
IL (1) IL126546A (is)
IS (1) IS2524B (is)
MA (1) MA24172A1 (is)
ME (1) ME00880B (is)
MY (1) MY121999A (is)
NO (1) NO324373B1 (is)
NZ (1) NZ332220A (is)
OA (1) OA10907A (is)
PL (1) PL189324B1 (is)
PT (1) PT900088E (is)
RS (1) RS49532B (is)
SA (1) SA97180024B1 (is)
SI (1) SI0900088T1 (is)
SK (1) SK282032B6 (is)
TN (1) TNSN97075A1 (is)
TR (1) TR199802231T2 (is)
TW (1) TW514529B (is)
UA (1) UA57734C2 (is)
UY (1) UY24544A1 (is)
WO (1) WO1997041896A2 (is)
ZA (1) ZA973874B (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0811386T3 (da) * 1996-05-07 2005-01-03 Pfizer Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) * 1999-05-10 2010-07-14 栄研化学株式会社 ホタルルシフェリンの安定化方法
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6884885B2 (en) 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
SI1542668T1 (sl) * 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
AP2005003250A0 (en) * 2002-09-17 2005-03-31 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
JP2006514923A (ja) * 2002-10-25 2006-05-18 ファイザー・プロダクツ・インク 注射可能な新規なデポ製剤
PL375603A1 (en) * 2002-10-25 2005-12-12 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
JP2006506396A (ja) * 2002-10-31 2006-02-23 ファイザー・プロダクツ・インク 固体医薬の液体複合体
US20040142039A1 (en) * 2002-10-31 2004-07-22 Pfizer Inc Solid and semi-solid polymeric ionic conjugates
EP1418492B1 (en) 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
CA2528192A1 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd Cristalline ziprasidone hcl and processes for preparation thereof
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
KR20060103947A (ko) * 2003-12-08 2006-10-04 더 아리조나 보드 오브 리전츠 온 비해프 오브 더 유니버시티 오브 아리조나 상승작용성 항암 조성물
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
EP1744750A2 (en) 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) * 2004-05-26 2006-03-30 Pfizer Products Inc. In vitro predictive method
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
CA2587710C (en) * 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
CA2599391A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
CN103288834B (zh) 2006-07-10 2015-07-15 Paion英国有限公司 短效苯并二氮杂*盐及其多晶型
EP2146577A1 (en) * 2007-05-18 2010-01-27 Scidose, Llc Ziprasidone formulations
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) * 2011-05-25 2014-12-17 上海医药工业研究院 卢拉西酮组合物
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1255462B (it) 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
NZ508303A (en) 1996-05-07 2001-07-27 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone) useful as a dopamine D2 antagonist
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
DK0811386T3 (da) 1996-05-07 2005-01-03 Pfizer Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
ATE257714T1 (de) 2004-01-15
KR20000010823A (ko) 2000-02-25
EP0900088A2 (en) 1999-03-10
NO985192L (no) 1998-11-06
SK282032B6 (sk) 2001-10-08
GEP20074185B (en) 2007-08-10
UA57734C2 (uk) 2003-07-15
SK150498A3 (en) 2000-01-18
ES2212809T3 (es) 2004-08-01
CA2251912C (en) 2003-06-03
US6232304B1 (en) 2001-05-15
HUP9902799A3 (en) 2000-12-28
IL126546A0 (en) 1999-08-17
HRP970237B1 (en) 2002-04-30
AR007002A1 (es) 1999-10-13
DE69727218T2 (de) 2004-11-18
UY24544A1 (es) 2000-09-29
US6399777B2 (en) 2002-06-04
EP0900088B1 (en) 2004-01-14
PL329928A1 (en) 1999-04-26
DE69727218D1 (de) 2004-02-19
CN1216923A (zh) 1999-05-19
EG24135A (en) 2008-08-06
TNSN97075A1 (fr) 2005-03-15
HU222451B1 (hu) 2003-07-28
WO1997041896A2 (en) 1997-11-13
DZ2220A1 (fr) 2002-12-03
BG64475B1 (bg) 2005-04-30
CO4600677A1 (es) 1998-05-08
CZ346198A3 (cs) 1999-09-15
MA24172A1 (fr) 1997-12-31
EA001731B1 (ru) 2001-08-27
AU1937297A (en) 1997-11-26
BG64474B1 (bg) 2005-04-30
CA2251912A1 (en) 1997-11-13
ID16866A (id) 1997-11-20
AP9700977A0 (en) 1997-07-31
PL189324B1 (pl) 2005-07-29
PT900088E (pt) 2004-04-30
RS49532B (sr) 2006-12-15
JP3579060B2 (ja) 2004-10-20
IS2524B (is) 2009-07-15
BR9709213A (pt) 1999-08-10
ZA973874B (en) 1998-11-06
AR045528A2 (es) 2005-11-02
BG102894A (en) 1999-09-30
IL126546A (en) 2001-01-28
TW514529B (en) 2002-12-21
NO985192D0 (no) 1998-11-06
TR199802231T2 (xx) 1999-02-22
HN1997000039A (es) 1997-06-26
SA97180024B1 (ar) 2005-12-24
YU17297A (sh) 1999-12-27
ME00880B (me) 2006-12-15
SI0900088T1 (en) 2004-04-30
OA10907A (en) 2001-10-26
HRP970237A2 (en) 1998-12-31
WO1997041896A3 (en) 1998-01-08
EA199800910A1 (ru) 1999-04-29
CZ297847B6 (cs) 2007-04-11
NZ332220A (en) 2000-03-27
HUP9902799A2 (hu) 1999-12-28
AU713711B2 (en) 1999-12-09
GT199700044A (es) 1998-10-02
DK0900088T3 (da) 2004-04-19
BG64475B2 (bg) 2005-04-30
NO324373B1 (no) 2007-10-01
US20010031756A1 (en) 2001-10-18
JPH11509866A (ja) 1999-08-31
MY121999A (en) 2006-03-31
AP796A (en) 1999-12-24

Similar Documents

Publication Publication Date Title
IS4880A (is) Innlyksa kompexar af arýl - heterósýklískum söltum
ID19430A (id) Senyawa senyawa heterosiklik
BR9709230A (pt) Composto
BR9509760A (pt) Composto
DE69713918D1 (de) Episulfid-Verbindung
DE69713026D1 (de) Positioniervorrichtung
BR9707051A (pt) Composto
DE59914748D1 (de) Kommutator-kleinmotor
DK0839989T3 (da) Udløselig forbindelse
BR9711205A (pt) Composto
EE9800374A (et) Sisemised või sünkroniseerimisega seotud täiustused
ID18027A (id) Garam amina
ID27766A (id) Garam-garam paroksetin
DE69717920D1 (de) Rotationsmaschine
EE9800375A (et) Sisemised või sünkroniseerimisega seotud täiustused
DE59501902D1 (de) Giessmasse
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
DE59706129D1 (de) Tensidhaltige formulierungen
BR9509740A (pt) Compostos 18-nor-vitamina d
DE69515735D1 (de) Phasenkomparator
KR950031850U (ko) 피조개 채취기
BR9506516A (pt) Oxazolinas substituídas
SE9400475D0 (sv) Kompoundmotor
KR970056241U (ko) 자석부착 페이저
SE9801003D0 (sv) Kompoundmotor